Navigation Links
InterMune Reports First Quarter 2013 Financial Results and Business Highlights
Date:4/24/2013

ed on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking StatementsThis news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation InterMune's expectation regarding its anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in various European countries, including England, Wales, Italy, Finland, Ireland, the Netherlands and Spain; the estimated size of the patient population in Canada suffering from IPF and InterMune's expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof; InterMune's expectation regarding the results of the ASCEND study, including the timing of availability of such results, and the prospects of success thereof and meeting the goal of bringing Esbriet to IPF patients in the United States;  InterMune's expectation in building its Esbriet franchise in North America; and InterMune's projected revenue from sales of Esbriet and operating expenses for 2013.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Flagship Biosciences Announces Relocation and Expansion 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... Chicago The global biotechnology industry will face ... ethical and regulatory fights to the rigors of engineering ... will compare with what immediately confronts the 20,000 convention ... can you really believe? , ,A walk-through in ...
... been a center for innovation and discovery. From medicine ... were made right here in our state. Today, amid ... taken the lead. , ,From developing innovative new ... relieve its dependence on foreign oil to working to ...
... The biotechnology industry has a job to do, former ... by thousands at the BIO Chicago conference. , ,He called ... guard against pandemics, create crops that can feed more of ... ethanol, and confront global warming head on. , ,Clinton's vision ...
Cached Biology Technology:My-oh, it's BIO! Where sales hype and science collide 2Making Wisconsin the biotechnology leader 2Making Wisconsin the biotechnology leader 3Clinton says world needs biofuels, GM crops, and more answers 2Clinton says world needs biofuels, GM crops, and more answers 3
(Date:8/27/2014)... Outstanding basic research, a growing focus on translating ... care have earned the Herbert Irving Comprehensive Cancer ... and NewYork-Presbyterian Hospital an $18 million, five-year Cancer ... (NCI). The grant renews the center,s status as ... in New York City and one of only ...
(Date:8/27/2014)... growing number of studies have shown that ... pathogenesis of Parkinson,s disease. Previous studies from ... University in China have shown that baicalin ... reduced divalent metal transporter 1 expression, and ... nigra of rotenone-induced Parkinson,s disease rats. However, ...
(Date:8/27/2014)... As of seven hours ago the Happy Camp Complex ... Northern California, the July complex had consumed 35,530 as ... seventeen fires on the Happy Camp Ranger District of ... the area on August 11, 2014. All but three ... following is a list of contained fires and their ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Happy Camp and July Fire Complexes in California 2
... Muenchen (TUM) have been awarded prestigious ERC Grants: ... the development of drugs to combat multi-resistant germs; Prof. ... cellular components; 1.6 million goes to Prof. Andrzej Buras, ... particles; Prof. Daniel Cremers (1.98 million) is working on ...
... makers, industry, researchers and the public have a new ... the Bioenergy Knowledge Discovery Framework, or KDF, developed by ... by the Department of Energy. The new site ... from reports, technical data and a list of experts ...
... An international group of stem cell scientists, bioethicists ... today for specific measures designed to counter secrecy and ... of data, materials and collective management of intellectual property ... the Hinxton Groupso named for the British city where ...
Cached Biology News:Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 2Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 3Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 4Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 5Nearly 10 million euros ($13.6 million) in ERC grants for 6 Technische Universitaet Muenchen researchers 6New DOE bioenergy website has ORNL roots 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 3
...
...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) Sensitivity: around ...
Biology Products: